Finance

Lists
Why is N1VS34 down 7,17%?
Dive Deeper
N1VS34:BVMF
Novartis AG Bdr
74,34 BRL
-7,17%
(-5,74) 1D
14-окт., 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for N1VS34...
Open
80,09 BRL
High
80,09 BRL
Low
73,43 BRL
Mkt. cap
300,82 млд
Avg. vol.
201,00
Volume
114,00
52-wk high
87,30 BRL
52-wk low
65,03 BRL
Shares outstanding
2,03 млд
No. of employees
75 миң
Open
80,09 BRL
High
80,09 BRL
Low
73,43 BRL
Mkt. cap
300,82 млд
Avg. vol.
201,00
Volume
114,00
52-wk high
87,30 BRL
52-wk low
65,03 BRL
Shares outstanding
2,03 млд
No. of employees
75 миң
News stories
From web sources and news partners
Global Arbitration Review
Global Arbitration Review
·
1 саат мурун
US biotech company enforces eye treatment award against Novartis
Quiver Quantitative
Quiver Quantitative
·
2 саат мурун
Why Novartis (NVS) Stock Is Up Today
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG Bdr
CEOVasant Narasimhan
Employees75,3 миң
Founded1996-ж., 7-мар.
HeadquartersБазель, Базель-Штадт, Швейцария
SectorPharmaceutical industry
Next call 13 күндөн кийин
27-окт., шейш., 18:40
Fiscal period
Q3 2026
- / 2,28 USD
Revenue / Est. (USD)
- / 14,67 млд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
14,36 млд
13,86 млд
13,52 млд
14,95 млд
Cost of goods sold
3,54 млд
3,54 млд
3,44 млд
3,68 млд
Cost of revenue
3,54 млд
3,54 млд
3,44 млд
3,68 млд
Research and development expenses
2,86 млд
2,84 млд
2,78 млд
2,74 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,30 млд
3,44 млд
3,14 млд
3,23 млд
Operating expense
6,24 млд
6,46 млд
5,96 млд
6,10 млд
Total operating expenses
9,77 млд
10,00 млд
9,40 млд
9,78 млд
Operating income
4,58 млд
3,86 млд
4,12 млд
5,18 млд
Other non operating income
-7,00 млн
-130,00 млн
4,00 млн
19,00 млн
EBT including unusual items
4,20 млд
3,22 млд
3,84 млд
4,27 млд
EBT excluding unusual items
4,29 млд
3,49 млд
3,78 млд
4,73 млд
Income tax expense
266,00 млн
814,00 млн
683,00 млн
1,01 млд
Effective tax rate
6,34%
25,30%
17,79%
23,71%
Other operating expenses
70,00 млн
190,00 млн
42,00 млн
127,00 млн
Net income
3,93 млд
2,41 млд
3,16 млд
3,26 млд
Net profit margin
27,36%
17,38%
23,34%
21,83%
Earnings per share
2,25
2,03
1,99
2,41
Interest and investment income
-
373,00 млн
-
-
Interest expense
-281,00 млн
-304,00 млн
-343,00 млн
-462,00 млн
Net interest expenses
-281,00 млн
69,00 млн
-343,00 млн
-462,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
5,78 млд
4,96 млд
5,24 млд
6,30 млд
Gain or loss from assets sale
81,00 млн
80,00 млн
-159,00 млн
-247,00 млн
AI content may include mistakes. Learn more
Google колдонмолору